Radiopharm Theranostics receives A$5,885,131 R&D refund

Radiopharm Theranostics Limited reports receiving an Australian R&D tax refund for the 2025 financial year totaling A$5,885,131, including A$104,475 of interest.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited reports receiving an Australian R&D tax refund for the 2025 financial year totaling A$5,885,131, including A$104,475 of interest. This payment comes from the Australian Government’s R&D tax incentive program, which offers a refundable tax offset of up to 43.5% for eligible activities.

The company states that this non-dilutive funding will support continued development of its radiopharmaceutical portfolio for diagnostic and therapeutic use in oncology, where it is running one Phase 2 and five Phase 1 clinical trials across several solid tumor types.

Key Figures

R&D tax refund (2025 FY): A$5,885,131 Interest included in refund: A$104,475 R&D tax offset rate: up to 43.5% +1 more

4 metrics

R&D tax refund (2025 FY) A$5,885,131 Australian Government R&D tax incentive refund for 2025 financial year

Interest included in refund A$104,475 Interest component included in total R&D tax refund

R&D tax offset rate up to 43.5% Refundable tax offset rate under Australian Government R&D tax incentive

Clinical trials in pipeline 1 Phase 2 and 5 Phase 1 Oncology radiopharmaceutical clinical program in solid tumors

Key Terms

R&D tax incentive, refundable tax offset, clinical-stage biopharmaceutical company, radiopharmaceuticals, +1 more

5 terms

R&D tax incentive financial

"The refund is received as part of the Australian Government’s R&D tax incentive"

A research and development (R&D) tax incentive is a government program that returns part of a company’s spending on developing new products, processes, or technologies, similar to getting a discount or rebate for innovation costs. For investors this matters because it lowers effective development costs, improves cash flow and margins, and can speed up projects—factors that affect profitability, risk and the valuation of companies pursuing new growth.

refundable tax offset financial

"provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%"

clinical-stage biopharmaceutical company financial

"Radiopharm Theranostics ... a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals"

A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.

radiopharmaceuticals medical

"developing innovative oncology radiopharmaceuticals for areas of high unmet medical need"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

Phase 2 medical

"The clinical program includes one Phase 2 and five Phase 1 trials"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

FAQ

What did Radiopharm Theranostics (RADX) announce in this Form 6-K?

Radiopharm Theranostics announced it has received an Australian R&D tax refund of A$5,885,131 for the 2025 financial year. This cash inflow supports ongoing development of its oncology radiopharmaceutical pipeline across multiple early-stage clinical trials.

How much R&D tax refund did Radiopharm Theranostics (RADX) receive?

Radiopharm Theranostics received a total R&D tax refund of A$5,885,131, which includes A$104,475 in interest. The payment relates to eligible research and development activities conducted during the company’s 2025 financial year under Australia’s R&D tax incentive program.

What is the Australian R&D tax incentive mentioned by Radiopharm Theranostics (RADX)?

The Australian R&D tax incentive is a government program providing a refundable tax offset of up to 43.5% for qualifying R&D activities. Radiopharm used this scheme to recover part of its oncology research spending for the 2025 financial year.

How will the R&D tax refund benefit Radiopharm Theranostics (RADX)?

Radiopharm Theranostics states the A$5,885,131 refund will provide important funding for continued development of its radiopharmaceutical products. This supports diagnostic and therapeutic programs in solid tumor cancers, including one Phase 2 and five Phase 1 clinical trials.

What stage is Radiopharm Theranostics’ (RADX) clinical pipeline in?

Radiopharm Theranostics describes itself as a clinical-stage radiotherapeutics company. Its pipeline currently includes one Phase 2 trial and five Phase 1 trials targeting various solid tumors, including lung, breast and brain cancers, using peptides, small molecules and monoclonal antibodies.

On which exchanges is Radiopharm Theranostics (RADX) listed?

Radiopharm Theranostics is listed on the Australian Securities Exchange under the symbol RAD and on Nasdaq under the symbol RADX. The company focuses on radiopharmaceutical products for cancer diagnosis and therapy in areas of high unmet medical need.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/06/2026 - 07:00 AM Accepted by SEC EDGAR 07/06/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on July 3, 2026 titled:

“Radiopharm Receives $5.9M R&D Tax Incentive”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

1

EXHIBITS

Exhibit Number		Description
99.1		Radiopharm Receives $5.9M R&D Tax Incentive

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: July 3, 2026	By:	/s/ Nathan Jong
		Nathan Jong
		Company Secretary

3

Exhibit 99.1

ASX ANNOUNCEMENT
3 July 2026

Radiopharm Receives $5.9M R&D Tax Incentive

Sydney, Australia – 3 July 2026 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has received its research and development (R&D) tax refund for the 2025 financial year, totalling A$.5,885,131, including A$104,475 interest.

The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%.

The refund received by Radiopharm will provide important funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields

Precision AQ (formerly Stern IR)

E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

ASX ANNOUNCEMENT
3 July 2026

Media
Matt Wright
NWR Communications

P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 RADIOPHARM RECEIVES $5.9M R&D TAX INCENTIVE 11.7 KB